Prashant Kesharwani

29.3k total citations · 9 hit papers
568 papers, 20.2k citations indexed

About

Prashant Kesharwani is a scholar working on Molecular Biology, Biomaterials and Biomedical Engineering. According to data from OpenAlex, Prashant Kesharwani has authored 568 papers receiving a total of 20.2k indexed citations (citations by other indexed papers that have themselves been cited), including 252 papers in Molecular Biology, 165 papers in Biomaterials and 118 papers in Biomedical Engineering. Recurrent topics in Prashant Kesharwani's work include RNA Interference and Gene Delivery (147 papers), Nanoparticle-Based Drug Delivery (146 papers) and Nanoplatforms for cancer theranostics (69 papers). Prashant Kesharwani is often cited by papers focused on RNA Interference and Gene Delivery (147 papers), Nanoparticle-Based Drug Delivery (146 papers) and Nanoplatforms for cancer theranostics (69 papers). Prashant Kesharwani collaborates with scholars based in India, Iran and Saudi Arabia. Prashant Kesharwani's co-authors include Nilesh Jain, Keerti Jain, Arun K. Iyer, Amirhossein Sahebkar, Bapi Gorain, Umesh Gupta, Afsana Sheikh, Rakesh Kumar Tekade, Hira Choudhury and Mohammed A. S. Abourehab and has published in prestigious journals such as Advanced Materials, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Prashant Kesharwani

524 papers receiving 19.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dendrimer as nanocarrier for drug delivery

2013 843 citations Prashant Kesharwani et al. profile →
Dendrimer toxicity: Let's meet the challenge

2010 526 citations Prashant Kesharwani et al. International Journal of Pharmaceutics profile →
A comprehensive review on polyelectrolyte complexes

2017 346 citations Prashant Kesharwani et al. profile →
An overview of application of silver nanoparticles for biomaterials in dentistry

2018 296 citations Prashant Kesharwani et al. profile →
Advancements in nanoparticle-based treatment approaches for skin cancer therapy

2023 225 citations Prashant Kesharwani et al. Molecular Cancer profile →
Gold nanoparticles and gold nanorods in the landscape of cancer therapy

2023 214 citations Prashant Kesharwani, Afsana Sheikh et al. Molecular Cancer profile →
Recent update on electrospinning and electrospun nanofibers: current trends and their applications

2022 169 citations Arif Nadaf, Nazeer Hasan et al. profile →
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

2023 129 citations Afsana Sheikh, Prashant Kesharwani et al. Molecular Cancer profile →
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches

2023 123 citations Nazeer Hasan, Arif Nadaf et al. Molecular Cancer profile →

Peers

Countries citing papers authored by Prashant Kesharwani

Since Specialization

Citations

This map shows the geographic impact of Prashant Kesharwani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prashant Kesharwani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prashant Kesharwani more than expected).

Fields of papers citing papers by Prashant Kesharwani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prashant Kesharwani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prashant Kesharwani. The network helps show where Prashant Kesharwani may publish in the future.

Co-authorship network of co-authors of Prashant Kesharwani

This figure shows the co-authorship network connecting the top 25 collaborators of Prashant Kesharwani. A scholar is included among the top collaborators of Prashant Kesharwani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prashant Kesharwani. Prashant Kesharwani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression 2025 ·Molecular Cancer ·(unknown), (unknown), (unknown), Prashant Kesharwani, Amirhossein Sahebkar	1
2	Advances in PLGA-based polymeric nanocarriers for colorectal cancer therapy: overcoming chemoresistance through controlled delivery strategies 2025 ·Molecular Cancer ·Mohid S. Khan, (unknown), Taha Alqahtani, (unknown), Garima Gupta, Khang Wen Goh, Amirhossein Sahebkar, Prashant Kesharwani	3
3	Exploring the efficacy and mechanisms of exemestane-loaded nanoparticles in targeted breast cancer therapy 2025 ·Biomaterials Advances ·Monika Chauhan, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Khang Wen Goh, Garima Gupta, Amirhossein Sahebkar, Prashant Kesharwani	0
4	Resveratrol in anti-biofilm therapy: Mechanisms, molecular derivatives, and emerging drug delivery strategies 2025 ·Fitoterapia ·Mahboobeh Ghasemzadeh Rahbardar, Prashant Kesharwani, Amirhossein Sahebkar	0
5	Stimuli-responsive nanotheranostic systems conjugated with AIEgens for advanced cancer bio-imaging and treatment 2024 ·Journal of Controlled Release ·Fatemeh Oroojalian, (unknown), Prashant Kesharwani, Amirhossein Sahebkar	11
6	Exploring the evolutionary links: Innate immunity in bacteria and eukaryotes 2024 ·Process Biochemistry ·(unknown), (unknown), (unknown), (unknown), Prashant Kesharwani, Amirhossein Sahebkar	2
7	Identification of novel biomarkers and potential molecular targets for uterine cancer using network-based approach 2024 ·Pathology - Research and Practice ·(unknown), Md. Zubbair Malik, Bhavya Alankar, Farhan Jalees Ahmad, Ravins Dohare, Ritu Chauhan, Prashant Kesharwani, Harleen Kaur	1
8	New opportunities for antioxidants in amelioration of neurodegenerative diseases 2024 ·Mechanisms of Ageing and Development ·(unknown), (unknown), (unknown), (unknown), Arif Nadaf, Nazeer Hasan, Prashant Kesharwani, Farhan Jalees Ahmad	12
9	The clinical prognostic significance of miR-140–5p expression in patients with cancer: A Meta and Bioinformatic analysis 2024 ·Pathology - Research and Practice ·Mehran Pashirzad, Prashant Kesharwani, Amirhossein Sahebkar	1
10	Small molecules targeting mitochondria as an innovative approach to cancer therapy 2024 ·Cellular Signalling ·(unknown), Rana Chatterjee, (unknown), (unknown), Abdulrhman Alsayari, Shadma Wahab, Amirhossein Sahebkar, Prashant Kesharwani, Rambabu Dandela	2
11	Dendrimer-Encapsulated Curcumin: Illuminating pathways to cancer treatment excellence 2024 ·European Polymer Journal ·(unknown), (unknown), Prashant Kesharwani, Amirhossein Sahebkar	4
12	Alkaloids in Cancer therapy: Targeting the tumor microenvironment and metastasis signaling pathways 2024 ·Fitoterapia ·(unknown), Elaheh Amini, (unknown), (unknown), Saeed Mohammadian Haftcheshmeh, Saurav Kumar Jha, Prashant Kesharwani, Abolfazl Shakeri, Amirhossein Sahebkar	8
13	Advancements in biosensor technologies for fibrinogen detection in cardiovascular disorders 2024 ·Talanta ·(unknown), Wael Almahmeed, Prashant Kesharwani, Amirhossein Sahebkar	1
14	Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers 2024 ·Molecular Cancer ·Prashant Kesharwani, (unknown), Saurav Kumar Jha, (unknown), Salem Salman Almujri, Waleed Hassan Almalki, (unknown)	40
15	COVID-19 diagnosis on the basis of nanobiosensors’ prompt interactivity: A holistic review 2024 ·Pathology - Research and Practice ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hassan Mahmoodi, (unknown), (unknown), Prashant Kesharwani, Ali Mohammad Amani, Amirhossein Sahebkar	0
16	Effects of dietary curcumin on gene expression: An analysis of transcriptomic data in mice 2024 ·Pathology - Research and Practice ·Maryam Mahjoubin‐Tehran, A. M. Mahedi Hasan, Ali H. Eid, Wael Almahmeed, Prashant Kesharwani, Alexandra E. Butler, (unknown), Amirhossein Sahebkar	1
17	Bioinformatic analysis of the molecular targets of curcumin in colorectal cancer 2024 ·Pathology - Research and Practice ·Ali Mahmoudi, Tannaz Jamialahmadi, Prashant Kesharwani, Amirhossein Sahebkar	6
18	Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer 2023 ·International Journal of Pharmaceutics ·Nazeer Hasan, Mohammad Imran, (unknown), (unknown), Kashif Haider, M. Moshahid Alam Rizvi, Afsana Sheikh, Prashant Kesharwani, Gaurav Jain, Farhan Jalees Ahmad	47
19	Psidium guajava induces cytotoxicity in human malignant glioblastoma cell line: Role of reactive oxygen species 2023 ·Toxicology in Vitro ·Azar Hosseini, Mohaddeseh Sadat Alavi, (unknown), Arezoo Rajabian, Amir R. Afshari, Prashant Kesharwani, Amirhossein Sahebkar	5
20	Drug loaded bioglass nanoparticles and their coating for efficient tissue and bone regeneration 2023 ·Journal of Non-Crystalline Solids ·(unknown), Nazeer Hasan, (unknown), (unknown), Mohammad, (unknown), Prashant Kesharwani, Farhan Jalees Ahmad	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact